Dr. Stephanie Dwyer Kaluzna and CardioScripts co-host, Dr. Tracy Macaulay, discuss the PARADISE-MI trial.
0:00-0:25: Introduction
0:26-1:19: Introduction of Dr. Stephanie Dwyer Kaluzna
1:20-6:14: PARADISE-MI Overview
6:15-7:56: Overall Thoughts
7:57-10:28: Use of ACE-I/ARB in MI
10:30-13:43: Background Therapy Considerations
13:44-18:08: Applicability and Feasibility of Use
18:09-19:24: Final Thoughts
19:25-20:02: Closing
References:
PARADISE-MI Trial: Design and baseline characteristics: Jering KS, Claggett B, Pfeffer MA, et al. Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics [published online ahead of print, 2021 Apr 12]. Eur J Heart Fail. 2021;10.1002/ejhf.2191. doi:10.1002/ejhf.2191
AIRE Trial: Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet. 1993;342(8875):821-828.
VALIANT Trial: McMurray J, Solomon S, Pieper K, et al. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). J Am Coll Cardiol. 2006;47(4):726-733. doi:10.1016/j.jacc.2005.09.055
EPHESUS Trial: Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction [published correction appears in N Engl J Med. 2003 May 29;348(22):2271]. N Engl J Med. 2003;348(14):1309-1321. doi:10.1056/NEJMoa030207
Timing of initiation of eplerenone in EPHESUS: Adamopoulos C, Ahmed A, Fay R, et al. Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial. Eur J Heart Fail. 2009;11(11):1099-1105. doi:10.1093/eurjhf/hfp136
CardioScripts 